Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alexandra Brooks

Physician Assistant Anna, TX Physician Assistant

NPI 1497137756 CMS profile 11050073

2100 W White St Ste 120, Anna, TX 75409

Open in the dashboard

General payments

$9,061

535 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexandra Brooks of Anna, TX is reported in the CMS Open Payments database as having received $9,061 across 535 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,638 121
2024 General $2,571 139
2023 General $2,493 139
2022 General $1,364 83
2021 General $996 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexandra Brooks
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alexandra Brooks were reported at $1,638. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alexandra Brooks Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $996 $132 $37–$438 $132
2022 $1,364 $155 $48–$522 $149
2023 $2,493 $167 $52–$557 $160
2024 $2,571 $178 $55–$600 $164
2025 $1,638 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,560 159 payments
  2. Dermavant Sciences, Inc. $1,560 83 payments
  3. Regeneron Healthcare Solutions, Inc. $832 36 payments
  4. Janssen Biotech, Inc. $760 47 payments
  5. Arcutis Biotherapeutics, Inc. $561 77 payments
  6. Sun Pharmaceutical Industries Inc. $531 31 payments
  7. Genzyme Corporation $444 24 payments
  8. LEO Pharma Inc. $241 11 payments
  9. UCB, Inc. $221 7 payments
  10. Incyte Corporation $181 12 payments
  11. Other $1,170 48 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,410 525 payments
  2. Education $651 10 payments
Products named General payments · program years 2021–2025
  1. VTAMA $1,593 86 payments
  2. SKYRIZI Immunology $1,088 65 payments
  3. DUPIXENT Immunology $844 39 payments
  4. RINVOQ $763 44 payments
  5. TREMFYA $745 37 payments
  6. DUPIXENT Inflammation And Immunology $548 24 payments
  7. SKYRIZI Immunology $473 40 payments
  8. Zoryve $333 51 payments
  9. DUPIXENT Immunology And Inflammation $247 9 payments
  10. ADBRY $229 10 payments
  11. Other $2,427 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

764

Median for Physician Assistant: 241

Drug cost

$445,977

Median for Physician Assistant: $4,110

Branded share of claims

18.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 15 $326,925
Dupixent Pen Dupilumab Brand 18 $69,503
Vtama Tapinarof Brand 15 $21,619
Zoryve Roflumilast Brand 11 $9,334
Clobetasol Propionate Generic 137 $6,062
Ketoconazole Generic 185 $3,920
Metronidazole Generic 26 $1,507
Fluorouracil Generic 17 $1,145
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 44 $1,098
Clindamycin Phos-Benzoyl Perox Clindamycin Phos/Benzoyl Perox Brand 20 $933

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$159,117

Medicare's payments for the services billed

Medicare patients

782

Average age 74

Services billed

5,032

435 women, 347 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 30%
Diabetes 29%
Atrial fibrillation 20%
Chronic kidney disease 18%
Depression 15%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $664
$664 15 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $250
  • GENZYME CORPORATION $213
  • SANOFI-AVENTIS U.S. LLC $100
$563 18 —
SKYRIZI
  • AbbVie, Inc. $560
$560 15 —
Zoryve
  • Arcutis Biotherapeutics, Inc. $137
$137 11 —
RINVOQ
  • AbbVie, Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

535 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record